CASE STUDY
Commercial Viability Assessment and Strategic Pivot
Strategic Assessment That Shaped a Multi-Year Growth Initiative. Commercial viability assessment revealed that building their own capital equipment business would capture significantly more strategic value than OEM partnerships
The Challenge
A bioprocessing supplier with breakthrough capital equipment technology needed to determine the optimal commercialization path. After five years of R&D investment, they were at a strategic crossroads: build their own capital equipment business or partner through OEM arrangements.
They commissioned MKA to conduct an independent commercial viability assessment—examining market demand, competitive dynamics, and go-to-market options. What began as market research evolved into strategic analysis that fundamentally shaped their commercialization approach.
- Industry: Bioprocessing / Biopharma Manufacturing
- Services: Commercial Viability Assessment, Market Research, Competitive Analysis, Strategic Recommendation
- Timeline: Initial 3-month assessment phase
- Company Type: Established bioprocessing consumables supplier exploring capital equipment market entry
Company Background
The company was an established bioprocessing consumables supplier with strong brand equity, trusted customer relationships across biopharma companies and CDMOs, and an established reputation for quality and technical support. After spending 5 years developing breakthrough capital equipment technology, leadership needed to decide how to commercialize the innovation.
The technology addressed real customer pain points including improving media preparation workflows, reducing contamination risk, and increasing process consistency in biopharma manufacturing. But the company operated in consumables—media, sera, buffers, and process liquids. Capital equipment represented new territory with different customer needs, sales cycles, service requirements, and competitive dynamics.
The Strategic Challenge
After validating the technical feasibility through five years of R&D investment, leadership faced an important strategic decision about how to commercialize the innovation.
Two paths were under consideration.
The first option was OEM Partnership: Partner with an established capital equipment manufacturer who would commercialize the technology under their brand. This offered faster market access and leveraged existing sales infrastructure.
The second option was Direct Business: Build their own capital equipment business line, capturing full commercial control but requiring new capabilities.
Both approaches had merit. The OEM path was operationally simpler and reduced risk. Building their own business offered greater strategic control but required significant capability development.
Rather than make this decision based on assumptions, leadership made the strategic choice to commission an independent commercial viability assessment. They needed objective analysis of market opportunity and demand validation, competitive positioning and differentiation potential, economic viability of each commercialization approach, and strategic implications for long-term value creation.
This is where MKA came in—to provide data-driven analysis that would inform one of the most significant strategic decisions in the company’s history.
Our Approach
01 | Comprehensive Market & Competitive Analysis
We conducted thorough market research to understand the bioprocessing capital equipment landscape including customer segments, purchase criteria, competitive solutions, pricing dynamics, and market trends.
We interviewed prospective customers to validate unmet needs, evaluated competitive equipment to identify differentiation opportunities, and assessed the economic value that improved workflows would deliver.
This analysis confirmed significant market opportunity existed and that the technology addressed genuine customer pain points—validating the core premise that commercialization made strategic sense.
02 | Strategic Asset & Capability Mapping
Beyond market analysis, we evaluated the company’s strategic positioning and existing assets.
Their existing strengths included strong brand equity in bioprocessing consumables, established customer relationships with target buyers, sales teams already calling on the same accounts, technical credibility that would transfer to equipment, and deep understanding of customer workflows and pain points.
Capability gaps included no capital equipment sales infrastructure, limited service and support capabilities, no established equipment manufacturing partnerships, and different sales cycles than consumables business.
We also examined where long-term value would be captured. Recurring revenue from consumables (cartridges), software licenses, and service contracts represented significant ongoing value beyond initial equipment sales.
03 | Build vs. Partner Strategic Analysis
We developed detailed scenarios comparing the two commercialization approaches.
The OEM Partnership Approach offered faster market access through partner’s infrastructure, lower upfront investment in new capabilities, and reduced operational complexity. However, it meant shared control over product positioning and pricing, limited capture of recurring revenue streams, partner ownership of direct customer relationships, and revenue share model versus full margin capture.
The Direct Business Approach provided full control over brand positioning and customer experience, capture of 100% of equipment and recurring revenue, direct customer relationships enabling feedback and innovation, and leverage of existing brand equity and customer trust. The tradeoffs included requiring building new capabilities (operationally complex), higher upfront investment, and longer timeline to market.
Our analysis showed that while the OEM path was operationally simpler, building their own business would capture substantially more strategic value over time—particularly given their existing market position and customer relationships.
04 | Strategic Recommendation & Business Case
Based on our analysis, we presented leadership with a recommendation: Build your own capital equipment business line.
The business case highlighted several critical factors.
For strategic positioning, they were uniquely positioned to succeed with existing customer relationships providing competitive advantage.
Market opportunity assessment validated demand from customers who already trusted their brand.
Value creation analysis showed the direct business model would capture equipment sales, recurring consumables, software licensing, and service revenue—versus contract manufacturing margins in OEM model.
Competitive differentiation potential came from offering integrated equipment plus consumables solution versus competitors selling equipment only.
Long-term growth perspective positioned the new business line as a strategic growth platform, not just licensing revenue.
The implementation path required building new capabilities, but these were achievable operational challenges with the right program leadership.
The recommendation reframed the initiative from “product launch” to “strategic business development”—changing scope, investment level, and organizational approach.
The Impact
Strategic Value Optimization
MKA’s assessment provided the strategic analysis needed to make an informed commercialization decision. By evaluating both OEM and direct business approaches objectively, we helped leadership understand the trade-offs and long-term implications of each path.
The analysis showed that building their own business would capture significantly more strategic value than OEM partnerships—including equipment revenue, recurring consumables, software licensing, and service contracts. This insight shaped the decision to pursue direct commercialization rather than the operationally simpler but strategically limiting OEM approach.
Market Validation & Investment Confidence
The commercial viability assessment confirmed that substantial market demand existed and that the technology addressed genuine customer pain points. This validation was critical for securing internal support and resources for what became a multi-year, multi-million dollar initiative.
Without clear evidence of market opportunity and strategic rationale, leadership might have pursued the lower-risk OEM approach or potentially abandoned the project altogether. The assessment provided the confidence needed to commit significant resources to building new business capabilities.
Strategic Clarity & Organizational Alignment
By reframing the initiative from “product launch” to “new business line creation,” MKA helped leadership understand the true scope and strategic importance of the opportunity. This clarity enabled better decision-making about resource allocation, organizational structure, and timeline expectations.
The assessment aligned stakeholders around building a strategic growth platform rather than simply licensing technology. This alignment was essential for securing the organizational commitment and resources needed for successful execution.
Foundation for Multi-Year Program
The commercial viability assessment became the strategic foundation for MKA’s subsequent 2.5-year engagement. Once the “build” decision was made, MKA provided program management leadership to establish business infrastructure, develop products, build sourcing partnerships, and drive the initiative to validation-ready status.
Without the initial strategic analysis and build/partner decision, this implementation work would have taken a different form—likely OEM partnership support rather than new business development. The strategic clarity from the assessment enabled focused execution on the right commercialization path.
Competitive Positioning & Market Entry
By commercializing under their own brand, the company established itself as a capital equipment innovator rather than a component supplier. This positioning enhanced overall brand equity in bioprocessing and signaled evolution from consumables provider to integrated solutions partner—opening opportunities for future innovation and deeper customer relationships.
The strategic decision to build rather than partner created competitive advantages that would compound over time through direct customer feedback, brand control, and capture of recurring revenue streams.
Facing a similar challenge?
Let’s discuss how we can help.